RHJA
CHRS icon

Rice Hall James & Associates’s Coherus Oncology CHRS Stock Holding History

Rice Hall James & Associates’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-213,748
Closed -$2.96M – 312
2021
Q2 		$2.96M Sell
213,748
-68,992
-24% -$977K 0.11% 150
2021
Q1 		$4.13M Buy
282,740
+72,245
+34% +$1.23M 0.13% 123
2020
Q4 		$3.66M Sell
210,495
-73,866
-26% -$1.32M 0.13% 126
2020
Q3 		$5.21M Sell
284,361
-166,571
-37% -$3.1M 0.21% 94
2020
Q2 		$8.05M Buy
450,932
+56,004
+14% +$948K 0.35% 81
2020
Q1 		$6.41M Sell
394,928
-302,625
-43% -$5.59M 0.36% 82
2019
Q4 		$12.6M Sell
697,553
-8,134
-1% -$150K 0.42% 92
2019
Q3 		$14.3M Buy
+705,687
New +$14.1M 0.51% 78

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Rice Hall James & Associates's CHRS Position: Q3 2021 in Review

Rice Hall James & Associates sold out of Coherus Oncology (CHRS) in Q3 2021, closing a stake of 213,748 shares — an estimated $2.96M sold.

Rice Hall James & Associates first reported a position in CHRS in Q3 2019 and held it in 8 quarters. The position peaked at $14.3M in Q3 2019. 187 funds tracked by Wall St. Rank hold CHRS as of Q3 2021.

  • Rice Hall James & Associates reported no remaining Coherus Oncology position as of Q3 2021 after selling out during the quarter.
  • Rice Hall James & Associates sold 213,748 Coherus Oncology shares in Q3 2021, an estimated $2.96M.
  • Rice Hall James & Associates first reported a position in Coherus Oncology in Q3 2019 and held it in 8 quarters.
  • Rice Hall James & Associates's Coherus Oncology position peaked at $14.3M in Q3 2019.
  • 187 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2021.

Based on Rice Hall James & Associates's 13F filing for Q3 2021, filed 9 Nov 2021.